WallStSmart

Envoy Medical Inc. (COCH)vsDexCom Inc (DXCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 2058832% more annual revenue ($4.82B vs $234,000). DXCM leads profitability with a 19.3% profit margin vs 0.0%. DXCM earns a higher WallStSmart Score of 72/100 (B).

COCH

Avoid

15

out of 100

Grade: F

Growth: 3.3Profit: 3.0Value: 6.7Quality: 6.0
Piotroski: 2/9Altman Z: -60.53

DXCM

Strong Buy

72

out of 100

Grade: B

Growth: 8.7Profit: 8.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.67
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

COCHUndervalued (+49.3%)

Margin of Safety

+49.3%

Fair Value

$1.30

Current Price

$0.64

$0.66 discount

UndervaluedFair: $1.30Overvalued
DXCMUndervalued (+89.6%)

Margin of Safety

+89.6%

Fair Value

$656.95

Current Price

$75.14

$581.81 discount

UndervaluedFair: $656.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COCH1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

DXCM4 strengths · Avg: 9.0/10
Return on EquityProfitability
31.5%10/10

Every $100 of equity generates 31 in profit

EPS GrowthGrowth
92.2%10/10

Earnings expanding 92.2% YoY

Operating MarginProfitability
21.4%8/10

Strong operational efficiency at 21.4%

Revenue GrowthGrowth
15.0%8/10

15.0% revenue growth

Areas to Watch

COCH4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$50.91M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
32.9x4/10

Premium valuation, high expectations priced in

Price/BookValuation
9.8x4/10

Trading at 9.8x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : COCH

The strongest argument for COCH centers on Debt/Equity.

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.

Bear Case : COCH

The primary concerns for COCH are EPS Growth, Market Cap, Return on Equity.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Key Dynamics to Monitor

COCH profiles as a value stock while DXCM is a mature play — different risk/reward profiles.

COCH carries more volatility with a beta of 1.86 — expect wider price swings.

DXCM is growing revenue faster at 15.0% — sustainability is the question.

DXCM generates stronger free cash flow (449M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (72/100 vs 15/100), backed by strong 19.3% margins and 15.0% revenue growth. COCH offers better value entry with a 49.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Envoy Medical Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Envoy Medical Corporation manufactures and markets an implantable hearing aid device. The company is headquartered in White Bear Lake, Minnesota.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Want to dig deeper into these stocks?